Statement Of Cash Flows [Abstract]

Pharming Group N.V. - Filing #1883078

Concept As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
USD
USD
13,674,000 USD
USD
13,674,000 USD
USD
USD
USD
15,996,000 USD
15,996,000 USD
Adjustments to reconcile profit (loss) [abstract]
Adjustments for finance costs
5,463,000 USD
6,196,000 USD
Adjustments for decrease (increase) in inventories
15,016,000 USD
6,153,000 USD
Adjustments for share-based payments
6,392,000 USD
9,056,000 USD
Adjustments for fair value losses (gains)
1,185,000 USD
114,000 USD
Adjustments for undistributed profits of associates
1,083,000 USD
694,000 USD
Other adjustments for non-cash items
1,576,000 USD
524,000 USD
Interest received, classified as operating activities
85,000 USD
53,000 USD
Income taxes paid (refund), classified as operating activities
1,235,000 USD
USD
Cash flows from (used in) operating activities
22,458,000 USD
37,842,000 USD
Cash flows from (used in) investing activities [abstract]
Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities
USD
4,589,000 USD
Purchase of property, plant and equipment, classified as investing activities
1,376,000 USD
10,739,000 USD
Purchase of intangible assets, classified as investing activities
601,000 USD
3,447,000 USD
Cash flows from (used in) investing activities
5,323,000 USD
21,305,000 USD
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing other equity instruments
2,281,000 USD
4,718,000 USD
Payments of lease liabilities, classified as financing activities
3,311,000 USD
3,217,000 USD
Interest paid, classified as financing activities
3,952,000 USD
4,448,000 USD
Cash flows from (used in) financing activities
4,982,000 USD
27,947,000 USD
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
22,799,000 USD
11,410,000 USD
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
7,381,000 USD
1,825,000 USD
Cash and cash equivalents
207,342,000 USD
191,924,000 USD
205,159,000 USD

Talk to a Data Expert

Have a question? We'll get back to you promptly.